Patents by Inventor Christine Menetrier-Caux

Christine Menetrier-Caux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10273306
    Abstract: The invention relates to a specific antibody directed against, for use for treating graft versus host disease.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: April 30, 2019
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Centre Leon Berard, Université d' Aix-Marseille
    Inventors: Gilles Marodon, Daniel Olive, Christine Menetrier-Caux
  • Publication number: 20180244780
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4? T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Application
    Filed: April 23, 2018
    Publication date: August 30, 2018
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 9975950
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: April 20, 2017
    Date of Patent: May 22, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Publication number: 20170275372
    Abstract: The invention relates to a specific antibody directed against, for use for treating graft versus host disease.
    Type: Application
    Filed: June 2, 2017
    Publication date: September 28, 2017
    Inventors: Gilles MARODON, Daniel OLIVE, Christine MENETRIER-CAUX
  • Publication number: 20170233478
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Application
    Filed: April 20, 2017
    Publication date: August 17, 2017
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 9695247
    Abstract: The invention relates to a specific antibody directed against, for use for treating graft versus host disease.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: July 4, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE LEON BERARD, UNIVERSITÉ D'AIX-MARSEILLE
    Inventors: Gilles Marodon, Daniel Olive, Christine Menetrier-Caux
  • Patent number: 9676852
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: June 13, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, Universite Claude Bernard—Lyon 1, Centre Leon Berard
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Publication number: 20160264666
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Application
    Filed: May 26, 2016
    Publication date: September 15, 2016
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Patent number: 9376493
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Grant
    Filed: March 29, 2012
    Date of Patent: June 28, 2016
    Assignees: INSERM (Institut National de la Sante et de la Recherche Mediacale), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, UNIVERSITE CLAUDE BERNARD, CENTRE LEON BERARD
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Publication number: 20150239978
    Abstract: The invention relates to a specific antibody directed against, for use for treating graft versus host disease.
    Type: Application
    Filed: September 3, 2013
    Publication date: August 27, 2015
    Inventors: Gilles Marodon, Daniel Olive, Christine Menetrier-Caux
  • Publication number: 20140086923
    Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.
    Type: Application
    Filed: March 29, 2012
    Publication date: March 27, 2014
    Applicants: INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITE D'AIX-MARSEILLE, INSERM (Institut National de la Sante et de la Recherche Medicale, CENTRE LEON BERARD, UNIVERSITE CLAUDE BERNARD - LYON 1
    Inventors: Julien Faget, Christophe Caux, Christine Menetrier-Caux, Jacques Nunes, Daniel Olive
  • Publication number: 20120309013
    Abstract: The present invention relates to a method making it possible to identify the patients, from among those affected by a given solid cancer, that have increased risk of premature death. Said method is based on the ex vivo analysis of the lymphocytic diversity of the patients on the basis of a biological sample containing lymphocytes. In fact, low lymphocytic diversity is related to a poor prognosis. Specifically, it is possible to set a diversity threshold, depending on the analysis technology used and the cancer affecting the patient, beyond which the life expectancy of the patient is significantly less than that, in general, of the patients affected by the same disease.
    Type: Application
    Filed: December 9, 2010
    Publication date: December 6, 2012
    Inventors: Christophe Caux, Jean-François Mouret, Christine Menetrier-Caux, Nicolas Pasqual, Thomas Bachelot, Manuarii Manuel, Jean-Yves Blay